Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: A total of 261 (58.9%) patients had representative tissue samples for RRM1 evaluation. Disease control rate, progression-free survival (PFS) and overall survival (OS) were substantially improved in patients with RRM-negative (neg) tumors receiving regimen B when compared with patients with RRM-positive (pos) tumors (68.8% versus 31.2%, P = 0.046, 6.90 months versus 3.93 months, P = 0.000 and 11.57 months versus 7.4 months, P = 0.002, respectively). Interaction analysis between RRM1-neg status and adenocarcinomas yielded a hazard ratio (HR) of 0.36 for death (P = 0.000). CONCLUSIONS:
|
Authors | A C Vilmar, E Santoni-Rugiu, J B Sorensen |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 24
Issue 2
Pg. 309-314
(Feb 2013)
ISSN: 1569-8041 [Electronic] England |
PMID | 23038758
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Biomarkers, Tumor
- Radiation-Sensitizing Agents
- Tumor Suppressor Proteins
- Deoxycytidine
- Vinblastine
- RRM1 protein, human
- Ribonucleoside Diphosphate Reductase
- Paclitaxel
- Cisplatin
- Vinorelbine
- Gemcitabine
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Phytogenic
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
(drug therapy, mortality)
- Cisplatin
(therapeutic use)
- Deoxycytidine
(analogs & derivatives, therapeutic use)
- Disease-Free Survival
- Female
- Humans
- Lung Neoplasms
(drug therapy, mortality)
- Male
- Middle Aged
- Paclitaxel
(therapeutic use)
- Prognosis
- Radiation-Sensitizing Agents
(therapeutic use)
- Ribonucleoside Diphosphate Reductase
- Survival Rate
- Tumor Suppressor Proteins
(biosynthesis, metabolism)
- Vinblastine
(analogs & derivatives, therapeutic use)
- Vinorelbine
- Young Adult
- Gemcitabine
|